Search Login Register

Glycogen Storage Disease Type IIb Summary

Description: An X-linked dominant multisystem disorder resulting in cardiomyopathy, myopathy and MENTAL RETARDATION. It is caused by mutation in the gene encoding LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2.

Also Known As: Danon Disease; Glycogen Storage Cardiomyopathy; Glycogen Storage Disease IIb; Glycogen Storage Disease Type 2B; Vacuolar Cardiomyopathy and Myopathy, X-linked Show All >>

Networked: 57 relevant articles (1 outcomes, 3 trials/studies) for this Disease

Key Drugs and Agents for Glycogen Storage Disease Type IIb

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. Free Radicals : 1 outcome in 1 result : IBA
  2. Antioxidants : 1 outcome in 1 result : IBA
  3. Gadolinium : 1 study in 2 results : IBA
  4. Carbonic Anhydrase Inhibitors : 1 study in 1 result : IBA
  5. Membrane Proteins (Integral Membrane Proteins) : 10 results : IBA
  6. Vacuolar myopathy : 9 results : IBA
  7. alpha-Glucosidases (Acid Maltase) : 7 results : IBA
  8. AMP-Activated Protein Kinases : 4 results : IBA
  9. Lysosomal-Associated Membrane Protein 2 : 4 results : IBA
  10. Glycogen : 4 results : IBA
Show All >>

Diseases Related to Glycogen Storage Disease Type IIb

  1. Muscular Diseases (Myopathy)
  2. Cardiomyopathies (Cardiomyopathy)
  3. Mental Retardation (Idiocy)
  4. Glycogen Storage Disease Type II (Pompe's Disease)
  5. Glycogen Storage Disease (Glycogenosis)
Show All >>

Key Therapies for Glycogen Storage Disease Type IIb

Efficacy Chart >>
  1. Heart Transplantation (Grafting, Heart) : 1 study in 7 results
  2. Implantable Defibrillators (Implantable Cardioverter-Defibrillator) : 2 results

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.